Sporadic late onset nemaline myopathy (SLONM)
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Sporadic late onset nemaline myopathy (SLONM). SLOAN without monoclonal protein: this accounts for about 40% of cases.
Classification
- SLOAN without monoclonal protein: this accounts for about 40% of cases
- SLONM with monoclonal protein: this accounts for about 6o% of cases
General features
Locked: subscribe to see this section.
Features of SLOAN with monoclonal protein
Locked: subscribe to see this section.
Associations of SLOAN without monoclonal protein
Locked: subscribe to see this section.
Magnetic resonance imaging (MRI) muscle: affected sites
Locked: subscribe to see this section.
Treatments of SLONM with monoclonal gammopathy
Locked: subscribe to see this section.
Acronym
Locked: subscribe to see this section.
References
- Naddaf E, Milone M, Kansagra A, Buadi F, Kourelis T. Sporadic late-onset nemaline myopathy: clinical spectrum, survival, and treatment outcomes. Neurology 2019; e298-e305.
- Paramalingam S, Dyke JM, Nossent JC. Sporadic late onset nemaline myopathy (SLONM) in an adult presenting with progressive muscle weakness. Eur J Rheumatol 2018; 6:1-3.
- Uruha A, Benveniste O. Sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance. Curr Opin Neurol 2017; 30:457-463.
- Schnitzler LJ, Schreckenbach T, Nadaj-Pakleza A, et al. Sporadic late-onset nemaline myopathy: clinico-pathological characteristics and review of 76 cases. Orphanet J Rare Dis 2017; 12:86.
- Kanamori T, Kusumoto S, Okita K, et al. Sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance mimicking POEMS syndrome. Rinsho Ketsueki 2018; 59:161-166.
- And 9 more. Subscribe to see the full list
